In individuals with obesity and type 2 diabetes mellitus, FGF21 analogs alleviate dyslipidemia and increase adiponectin levels, but have minimal effects on glycemic control, thereby highlighting interspecies differences in the actions of FGF21 (26). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.